Derisking assets to attract capital and rethinking funding models should be key priorities for Europe to retain its research pipeline.

While rare disease research has advanced significantly, related expertise and data are scattered across too many disconnected places.

Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide ...

At ASCO 2026, oral abstract presenters highlighted new and exciting central nervous system (CNS) tumour treatments.

If enacted, BINSA would give lawmakers the right to monitor and restrict American companies from signing biotech and pharma-focused deals with Chinese entities.

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

At ASCO 2026, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, evaluating Talzenna combined with Xtandi.

As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial edge.

Contraline could become the first to commercialise a reversible male contraceptive drug, provided the treatment is successful in Phase III.

AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk NMIBC.

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.